Safety and efficacy of GABAergic medications for treating alcoholism.
about
Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapsesIntroduction to behavioral addictionsNovel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulationWorld Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism.The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.High variability in the exposure of baclofen in alcohol-dependent patients.Genetically selected Marchigian Sardinian alcohol-preferring (msP) rats: an animal model to study the neurobiology of alcoholism.Neurosteroid modulators of GABA(A) receptors differentially modulate Ethanol intake patterns in male C57BL/6J miceModulation of resting brain cerebral blood flow by the GABA B agonist, baclofen: a longitudinal perfusion fMRI study.Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers.Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision.Gabapentin Therapy in Psychiatric Disorders: A Systematic Review.Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial.A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.Acute interaction of baclofen in combination with alcohol in heavy social drinkersAcute baclofen diminishes resting baseline blood flow to limbic structures: a perfusion fMRI study.Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review.Pharmacological approaches to reducing craving in patients with alcohol use disorders.Anticraving Effect of Baclofen in Alcohol-Dependent Patients.Use of Anti-Craving Agents in Soldiers with Alcohol Dependence Syndrome.Gabapentin Effect on Pain Associated with Heroin Withdrawal in Iranian Crack: a Randomized Double-blind Clinical Trial.Development of MLR and SVM Aided QSAR Models to Identify Common SAR of GABA Uptake Herbal Inhibitors used in the Treatment of Schizophrenia.
P2860
Q24240050-04E9145D-2488-4FD3-8768-B8C4A1FA8F5CQ24608377-F30A6382-512B-49F2-889A-105CE0264A4FQ26853630-718E3E6E-4183-435D-B891-A4A0CBB14080Q33319816-2DC12733-2A42-429A-817C-7F267282829BQ33757216-8E1DE8F2-A0CD-45B2-A0DB-BCF5F0EA4A64Q34038135-3A52B1F1-D3C0-4F5E-B298-12FA6439F513Q34561484-A989963A-2E11-483A-B358-E2F7265D7C94Q34976948-4AF9968C-9131-4B74-8CB8-7A19222BAC69Q35947830-68299B63-251A-40EA-AF03-443CEFE35A62Q36072485-E659B27E-CE44-4B71-900C-76C7CD4CECBFQ36231851-25B1F630-78ED-49C6-BD89-474C81F582EAQ36518678-2A3C6010-CE13-4D58-9D94-834206AFB094Q36829186-8A56BEC8-600F-477E-A140-30DB37F25B57Q36928610-13232E99-87C7-48FB-8C25-7D5BE884C9BBQ37060525-941B2F51-8F3A-4D57-BCCC-EA6BD17A6C22Q37163680-2A8F0F4A-B82C-4986-89F4-FB33E052C8A2Q37541691-200E00F1-7A9B-48C9-8809-8E532D96F765Q37708082-92D51D64-46E8-4C1E-AF95-5288E9924605Q40700363-C82CDCF5-0027-44D0-9659-14CE49305C80Q41172386-33E49713-B27F-4CAF-8823-E17664DDA5ADQ41855499-2A5F43B7-12D9-4086-8E5E-0E6AF300D48CQ48912516-B7DF64DF-6233-45A6-B988-02B0BF294EAF
P2860
Safety and efficacy of GABAergic medications for treating alcoholism.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Safety and efficacy of GABAergic medications for treating alcoholism.
@en
Safety and efficacy of GABAergic medications for treating alcoholism.
@nl
type
label
Safety and efficacy of GABAergic medications for treating alcoholism.
@en
Safety and efficacy of GABAergic medications for treating alcoholism.
@nl
prefLabel
Safety and efficacy of GABAergic medications for treating alcoholism.
@en
Safety and efficacy of GABAergic medications for treating alcoholism.
@nl
P2093
P2860
P1476
Safety and efficacy of GABAergic medications for treating alcoholism.
@en
P2093
Bankole A Johnson
Hugh Myrick
Robert M Swift
P2860
P304
P356
10.1097/01.ALC.0000153542.10188.B0
P577
2005-02-01T00:00:00Z